Reporting of adverse events for marketed drugs: Need for strengthening safety database
Pharmacovigilance is an evolving discipline in the Indian context. However, there is limited regulatory guidance for adverse event reporting outside the purview of clinical trials. There are number of deficiencies in the framework for adverse event reporting from the perspective of pharma industry,...
Main Author: | Aditi Anand Apte |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Perspectives in Clinical Research |
Subjects: | |
Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2016;volume=7;issue=3;spage=111;epage=114;aulast=Apte |
Similar Items
-
Adverse events in patients with leprosy on treatment with thalidomide
by: Paula Lana de Miranda Drummond, et al.
Published: (2019-04-01) -
Drug Safety Crises Management in Pharmacovigilance
by: Gloria Shalviri, et al.
Published: (2018-05-01) -
Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions
by: Pierre Karapetiantz, et al.
Published: (2018-05-01) -
Using the theory of planned behavior to predict Texas pharmacists' intention to report serious adverse drug events
by: Gavaza, Paul, 1972-
Published: (2010) -
Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
by: Riko Satake, et al.
Published: (2021-07-01)